aldosterone has been researched along with Dyslipidemia in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects." | 7.79 | Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013) |
| "These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism." | 3.85 | Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder. ( Kim, IK; Olatunji, LA; Seok, YM; Usman, TO, 2017) |
| "Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects." | 3.79 | Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013) |
| "Torcetrapib was the first CETP inhibitor to enter a large-scale, prospective, placebo-controlled interventional trial, which was prematurely terminated in December 2006 because of excess cardiovascular and noncardiovascular mortality in the active treatment group." | 2.44 | Spotlight on HDL-raising therapies: insights from the torcetrapib trials. ( Chapman, MJ; Guérin, M; Kontush, A, 2008) |
| "Arterial hypertension is one of the major coronary risk factors for cardiovascular diseases." | 2.43 | [Hypertension in postmenopausal women --selected pathomechanisms]. ( Kawecka-Jaszcz, K; Pośnik-Urbańska, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Walther, R | 1 |
| Julius, U | 1 |
| Tselmin, S | 1 |
| Schatz, U | 1 |
| Bornstein, SR | 1 |
| Graessler, J | 1 |
| Haas, AV | 1 |
| Baudrand, R | 2 |
| Easly, RM | 1 |
| Murray, GR | 1 |
| Touyz, RM | 1 |
| Pojoga, LH | 2 |
| Jeunemaitre, X | 2 |
| Hopkins, PN | 2 |
| Rosner, B | 1 |
| Williams, JS | 1 |
| Williams, GH | 2 |
| Adler, GK | 2 |
| Ohno, Y | 1 |
| Sone, M | 1 |
| Inagaki, N | 1 |
| Yamasaki, T | 1 |
| Ogawa, O | 1 |
| Takeda, Y | 1 |
| Kurihara, I | 1 |
| Umakoshi, H | 1 |
| Ichijo, T | 1 |
| Katabami, T | 1 |
| Wada, N | 1 |
| Ogawa, Y | 1 |
| Yoshimoto, T | 1 |
| Kawashima, J | 1 |
| Watanabe, M | 1 |
| Matsuda, Y | 1 |
| Kobayashi, H | 1 |
| Shibata, H | 1 |
| Miyauchi, S | 1 |
| Kamemura, K | 1 |
| Fukuoka, T | 1 |
| Yamamoto, K | 1 |
| Otsuki, M | 1 |
| Suzuki, T | 1 |
| Naruse, M | 1 |
| Long, HD | 1 |
| Lin, YE | 1 |
| Liu, MJ | 1 |
| Liang, LY | 1 |
| Zeng, ZH | 1 |
| Hall, JE | 1 |
| do Carmo, JM | 1 |
| da Silva, AA | 1 |
| Wang, Z | 1 |
| Hall, ME | 1 |
| Olatunji, LA | 1 |
| Usman, TO | 1 |
| Seok, YM | 1 |
| Kim, IK | 1 |
| Gupta, N | 1 |
| Garza, AE | 1 |
| Vaidya, A | 1 |
| Leopold, JA | 1 |
| Ferri, C | 1 |
| Romero, JR | 1 |
| Williams, J | 1 |
| Loscalzo, J | 1 |
| Pimenta, E | 1 |
| Calhoun, DA | 1 |
| Giordano, R | 1 |
| Marinazzo, E | 1 |
| Berardelli, R | 1 |
| Picu, A | 1 |
| Maccario, M | 1 |
| Ghigo, E | 1 |
| Arvat, E | 1 |
| King, AJ | 1 |
| Olivier, NB | 1 |
| Mohankumar, PS | 1 |
| Lee, JS | 1 |
| Padmanabhan, V | 1 |
| Fink, GD | 1 |
| Pośnik-Urbańska, A | 1 |
| Kawecka-Jaszcz, K | 1 |
| Kontush, A | 1 |
| Guérin, M | 1 |
| Chapman, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for aldosterone and Dyslipidemia
| Article | Year |
|---|---|
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
Topics: Aldosterone; Animals; Antihypertensive Agents; Dyslipidemias; Heart Conduction System; Hemodynamics; | 2015 |
[Hypertension in postmenopausal women --selected pathomechanisms].
Topics: Age Factors; Aldosterone; Angiotensin II; Blood Pressure; Body Mass Index; Dyslipidemias; Estrogen R | 2006 |
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Tr | 2008 |
9 other studies available for aldosterone and Dyslipidemia
| Article | Year |
|---|---|
Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Blood Component Removal; Cholesterol, LDL; Dehydroep | 2019 |
Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Caveolin 1; Cholesterol; Correlation of Data; Dyslipide | 2020 |
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
Topics: Adult; Aldosterone; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Essential Hypertensio | 2018 |
Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways.
Topics: Aldosterone; Animals; Apoptosis; Diet, High-Fat; Dyslipidemias; Hypertension; Insulin-Secreting Cell | 2013 |
Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder.
Topics: Aldosterone; Animals; Ataxia Telangiectasia Mutated Proteins; Cardiovascular Diseases; Contraceptive | 2017 |
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Aldehyde Reductase; Aldosterone; Animals; Blood Glucose; Ca | 2016 |
Aldosterone and metabolic dysfunction: an unresolved issue.
Topics: Aldosterone; Animals; Dyslipidemias; Humans; Hyperaldosteronism; Hypertension; Hypokalemia | 2009 |
Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas.
Topics: Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Aldosterone; B | 2010 |
Hypertension caused by prenatal testosterone excess in female sheep.
Topics: Aldosterone; Animals; Blood Pressure; Chlorides; Cholesterol; Disease Models, Animal; Dyslipidemias; | 2007 |